Spero Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Anson Funds Management LP and its affiliates reported a passive 2.9% beneficial ownership stake in Spero Therapeutics, Inc. as of June 30, 2025.